LUNG CANCER

Following ASCO 2024, Joshua K. Sabari, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss results from the LAURA trial investigating osimertinib following definitive chemoradiotherapy in patients with unresectable stage III non–small cell lung cancer with EGFR mutations.

Minesh Mehta, MD, discusses positive findings from the phase 3 METIS trial investigating TTFields therapy for brain metastases in NSCLC.

The METIS trial of tumor treating fields for the treatment of brain metastases in patients with non–small cell lung cancer met its primary end point, showing a statistically significant improvement in time to intracranial progression.

The combination of nivolumab and ipilimumab with chemotherapy shows significant long-term survival benefits in metastatic NSCLC, irrespective of PD-L1 expression or histology, as per updated 5-year data.

The combination of the adenovirus CAN-2409 and valacyclovir with continued immune checkpoint inhibitor therapy demonstrated favorable tolerability and induced a positive immune response.

Perioperative nivolumab led to a significant improvement in event-free survival in the phase 3 CheckMate 77T trial in patients with stage III N2 and stage III non-N2 non–small cell lung cancer.

During a Case-Based Roundtable® event, Julia Rotow, MD, continued a discussion on how biomarker testing for patients with non–small cell lung cancer impacts treatment decisions in the second article of a 2-part series.

Datopotamab deruxtecan was efficacious among patients with non-small cell lung cancer and baseline brain metastases who harbor actionable genomic alterations, according to an exploratory analysis of the phase 2 TROPION-Lung05 trial.

Patients with ROS1-positive non–small cell lung cancer responded to the next-generation inhibitor taletrectinib with acceptable toxicity.

Recent data shows that telehealth is comparable to quality of life to in-person visits for patients with advanced non–small cell lung cancer.

Osimertinib given after chemoradiation in patients with advanced non–small cell lung cancer harboring a EGFR mutation showed significant benefits.

Suresh Ramalingam, MD, principal investigator of the phase 3 LAURA trial, explains the study's evaluation of osimertinib in EGFR-mutated non-small cell lung cancer.

Adagrasib significantly improved responses among patients with KRASG12C-mutated locally advanced or metastatic non–small cell lung cancer.

In the case of a woman with metastatic non–small cell lung cancer, answer question of what you would do in terms of treatment and management, as well as questions about your practice.

A Prescription Drug User Fee Act target action date of September 25, 2024, has been set for the application of pembrolizumab plus chemotherapy in advanced mesothelioma.

AFM24 combined with atezolizumab has received a fast track designation from the FDA for treating advanced/metastatic non-small cell lung cancer without activating EGFR mutations.

While Dato-DXd numerically improved overall survival for patients with non-small cell lung cancer, the data did not show statistical significance. However, a clinically meaningful benefit was observed in a subgroup of patients.

An interim analysis of the CheckMate 77T trial shows that nivolumab plus chemotherapy improves event-free survival in resectable non-small cell lung cancer vs chemotherapy alone.

During a Case-Based Roundtable® event, Yasir Y. Elamin, MD, asked participants their perspectives on the use of targeted agents for patients with ALK+ non–small cell lung cancer in the second article of a 2-part series.

A correlation between non–small cell lung cancer and influenza shows a decrease in cancer survival rates.

Topline findings from the KICKSTART study showed that tomivosertib led to modest activity in non-small cell lung cancer (NSCLC).

Trials in small cell lung cancer and non–small cell lung cancer are fueling excitement in the oncology community.

The FDA has given the novel agent NVL-655 a breakthrough therapy designation for the treatment of patients with ALK-positive locally advanced or metastatic non-small cell lung cancer.

Nivolumab with ipilimumab did not lead to progression-free survival benefits in patients with unresectable stage III non-small cell lung cancer, missing the primary end point of the CheckMate -73L study.

Alex Spira, MD, PhD, discusses a subset analysis of the phase 3 MARIPOSA trial looking at dose interruptions during the course of amivantamab and lazertinib treatment for EGFR-mutant non-small cell lung cancer.